INHERITANCE
INtegrated HEart Research In TrANslational genetics of dilated Cardiomyopathies in Europe
| Coordinatore |
Organization address
address: VIALE GOLGI 19 contact info |
| Nazionalità Coordinatore | Non specificata |
| Sito del progetto | http://www.inheritanceproject.eu/index.php |
| Totale costo | 4˙028˙394 € |
| EC contributo | 2˙870˙791 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2 |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-01-01 - 2013-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
FONDAZIONE IRCCS POLICLINICO SAN MATTEO
Organization address
address: VIALE GOLGI 19 contact info |
IT (PAVIA) | coordinator | 573˙127.00 |
| 2 |
UNIVERSITAETSKLINIKUM HEIDELBERG
Organization address
address: IM NEUENHEIMER FELD 672 contact info |
DE (HEIDELBERG) | participant | 445˙808.00 |
| 3 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 330˙040.00 |
| 4 |
Health in Code SL
Organization address
city: A CORUNA contact info |
ES (A CORUNA) | participant | 246˙660.00 |
| 5 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 236˙755.00 |
| 6 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 209˙310.00 |
| 7 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | participant | 204˙208.00 |
| 8 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 200˙672.00 |
| 9 |
UNIVERSITA DEGLI STUDI DI PAVIA
Organization address
address: STRADA NUOVA 65 contact info |
IT (PAVIA) | participant | 184˙095.00 |
| 10 |
"AARHUS UNIVERSITETSHOSPITAL, SKEJBY"
Organization address
address: Brendstrupgaardsvej 100 contact info |
DK (AARHUS N) | participant | 168˙416.00 |
| 11 |
VASTERBOTTENS LANS LANDSTING
Organization address
address: Koksvagen 11 contact info |
SE (UMEA) | participant | 71˙700.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Inherited dilated cardiomyopathies (DCM) are monogenic disorders caused by mutations in more than 30 genes, characterised by substantial phenotype heterogeneity. DCM affects 1:2.500 individuals and is the major cause of heart transplantation and death for non-ischaemic heart failure in adolescents and young adults. Currently, less than 1% of patients with familial DCM are genotyped in Europe. The INHERITANCE (INtegrated HEart Research In TrANslational genetics of dilated Cardiomyopathies in Europe) consortium propose to investigate over 2,000 existing DCM patients and their relatives in order to translate novel insights on the aetiology and pathophysiology of inherited cardiomyopathies into innovative disease specific diagnostic and treatment strategies. The consortium members share common clinical, scientific and ethical standards with respect to patient care and family screening, and have individual expertise in the clinical management and molecular genetics of inherited cardiomyopathies. The INHERITANCE strategy is to integrate genomic, proteomic, structural and functional studies exploring the molecular cascades arising from causative mutations with innovative clinical assessments in order to understand disease expression, evolution and to explore novel therapeutic strategies both in humans and in animal models. The immediate benefits will include preclinical and presymptomatic diagnosis, family-tailored clinical work-up, optimisation of existing treatment strategies and cost-effective use of medical resources. In the medium term, these studies will catalyse the development of new disease specific protocols, and will provide a model for the exploration of ground-breaking genetic and pharmacological therapies.'